Considering those pathways beyond the UPR, RNA-seq analyses demonstrated that treatment with NXP800 impacted other key pathways, including AR, MYC, and E2F activity, implicated in prostate cancer treatment resistance (63, 66, 73). The gene discussed is AR; the disease is Familial prostate cancer.